LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.750
EU - Europa 6.077
AS - Asia 2.203
OC - Oceania 35
SA - Sud America 35
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 12
Totale 28.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.687
GB - Regno Unito 2.120
SE - Svezia 1.008
IT - Italia 982
HK - Hong Kong 923
CN - Cina 692
DE - Germania 616
UA - Ucraina 535
TR - Turchia 337
BG - Bulgaria 235
FI - Finlandia 191
FR - Francia 103
IN - India 59
RO - Romania 52
CA - Canada 48
ES - Italia 36
RU - Federazione Russa 33
IE - Irlanda 32
IR - Iran 30
NL - Olanda 27
VN - Vietnam 27
AU - Australia 25
JP - Giappone 25
KR - Corea 23
BR - Brasile 19
BE - Belgio 17
CH - Svizzera 14
MY - Malesia 14
PH - Filippine 14
PK - Pakistan 14
MX - Messico 12
DK - Danimarca 10
DZ - Algeria 10
NZ - Nuova Zelanda 10
PL - Polonia 10
TH - Thailandia 10
CL - Cile 8
LV - Lettonia 8
CZ - Repubblica Ceca 7
EU - Europa 7
AL - Albania 6
EG - Egitto 6
HR - Croazia 6
BD - Bangladesh 5
ID - Indonesia 5
IL - Israele 5
NO - Norvegia 5
SC - Seychelles 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CO - Colombia 4
MD - Moldavia 4
AT - Austria 3
GR - Grecia 3
IQ - Iraq 3
MA - Marocco 3
PT - Portogallo 3
SI - Slovenia 3
AR - Argentina 2
CR - Costa Rica 2
HU - Ungheria 2
KW - Kuwait 2
LK - Sri Lanka 2
PE - Perù 2
RS - Serbia 2
SG - Singapore 2
TW - Taiwan 2
UZ - Uzbekistan 2
A1 - Anonimo 1
AM - Armenia 1
BZ - Belize 1
EE - Estonia 1
ET - Etiopia 1
IS - Islanda 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LY - Libia 1
MM - Myanmar 1
NP - Nepal 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
ZA - Sudafrica 1
ZW - Zimbabwe 1
Totale 28.140
Salva come PNG Salva come JPEG
Città #
Fairfield 3.902
Woodbridge 1.885
Ashburn 1.845
Southend 1.737
Houston 1.549
Seattle 1.466
Cambridge 1.303
Wilmington 1.148
Chandler 1.125
Hong Kong 907
Jacksonville 893
Ann Arbor 758
Dearborn 680
Nyköping 675
Modena 369
Beijing 302
San Diego 285
Princeton 237
Sofia 232
Izmir 204
Eugene 193
Bremen 119
Helsinki 119
London 93
New York 88
Redwood City 68
Shanghai 58
Boardman 47
Milan 44
Falls Church 40
Rome 39
Norwalk 37
Guangzhou 35
Kilburn 34
Fremont 32
Dublin 30
Iasi 30
Nanjing 30
Hefei 28
Toronto 28
Kunming 24
Jinan 22
Dong Ket 20
Des Moines 19
Cortona 18
Parma 17
San Mateo 17
Brussels 16
Prescot 16
Bologna 15
Chiswick 15
Augusta 14
Chicago 14
Hounslow 12
Leawood 12
Nanchang 12
Fuzhou 11
Jönköping 11
Melbourne 11
Appignano 10
Barcelona 10
Huddinge 10
Mountain View 10
Philadelphia 10
Suwon 10
São Paulo 10
Ankara 9
Naples 9
Paris 9
Tokyo 9
Turin 9
Auckland 8
Hanover 8
Indiana 8
Islington 8
Riga 8
Shenyang 8
Wandsworth 8
Bangalore 7
Castelnovo 7
Chiang Mai 7
Dongguan 7
Grafing 7
Hanoi 7
Ottawa 7
Rimini 7
Sesto Fiorentino 7
Southwark 7
Veracruz 7
Zurich 7
Acton 6
Amsterdam 6
Bari 6
Boretto 6
Cagliari 6
Copenhagen 6
Desio 6
Frankfurt am Main 6
Madrid 6
Maser 6
Totale 23.305
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 374
Vitamin D and ovarian reserve: making clinical decisions 230
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 215
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 206
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 200
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 200
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 198
How Much Does AMH Really Vary in Normal Women? 194
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 193
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 191
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 190
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 190
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 189
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 188
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 188
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 187
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 186
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 185
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 184
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 182
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 182
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 182
MATER protein as substrate of PKCepsilon in human cumulus cells. 181
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 180
Adnexal Torsion during Pregnancy after Oocyte In Vitro Maturation and Intracytoplasmic Sperm Injection Cycle. 179
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 179
Anti-Mullerian hormone (AMH): what do we still need to know? 172
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 172
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 171
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 170
Periodontal disease and nitric oxide levels in low risk women with preterm labor 169
Primary ovarian insufficiency: autoimmune causes. 169
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 168
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 168
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 168
Utero-vaginal anastomosis in the treatment of cervical atresia 168
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 167
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 166
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 165
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 165
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 162
The physiology and clinical utility of anti-Mullerian hormone in women 161
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 159
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 158
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 158
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 158
Surgical treatment of ovarian dermoid cysts 157
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 156
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 156
Possibilities and Limits of Ovarian Reserve Testing in ART 156
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 156
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 156
Insulin sensitizing agents and their effect on adrenal androgens?: the reply 154
Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles 154
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 154
Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries 154
The ovarian follicular pool and reproductive outcome in women. 153
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 153
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 153
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 153
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 152
Perinatal outcomes following IVF with use of donor versus partner sperm 152
Anti-Müllerian hormone: clairvoyance or crystal clear? 150
The role of ovarian suspension in endometriosis surgery: a randomized controlled trial 150
How to personalize ovarian stimulation in clinical practice 149
Soluble L-selectin levels during controlled ovarian hyperstimulation 149
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 149
The management of vaginal agenesis: report of 104 cases 149
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 148
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 148
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 147
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 146
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 146
Recombinant human leptin in women with hypothalamic amenorrhea. 146
Whatever its variability, antimüllerian hormone remains the most stable hormonal predictor 146
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 146
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 146
Ultrastructural and DNA fragmentation analyses in swim-up selected human sperm 145
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 145
Short-term treatment of uterine fibromyomas with danazol 145
Thyroid function in early pregnancy I: Thyroid-stimulating hormone response to thyrotropin-releasing hormone 144
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 143
Rectus abdominis muscle endometriosis: Case report and review of the literature 143
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 143
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 143
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 143
Reply: The two sides of the individualization of controlled ovarian stimulation 142
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 142
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 142
The journey from the old to the new AMH assay: how to avoid getting lost in the values 141
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 141
Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis 140
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 140
The use of ovarian reserve markers in IVF clinical practice: a national consensus 139
The cardiovascular risk factor homocysteine is not elevated in young women with hyperandrogenism or hypoestrogenism 139
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 138
Total abdominal hysterectomy: A randomized study comparing two techniques 138
Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles 137
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women 137
The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin 136
Totale 16.397
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.270 0 0 0 0 0 0 0 0 0 393 874 1.003
2019/20207.007 500 250 184 476 749 1.118 1.224 794 817 311 384 200
2020/20216.127 572 353 511 521 769 374 570 871 261 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20242.389 95 153 122 270 479 180 510 456 68 56 0 0
Totale 28.545